← DOOMRADAR

markets · Published brief

Novartis trial setback sends shares lower

Novartis shares fell after a setback in the company's latest clinical trial. The supplied information does not specify the drug, trial outcome or scale of the decline.

By DoomRadar · Published on DoomRadar .

Why it matters

A major pharmaceutical trial failure can affect investors and the development prospects of a potential treatment.

Related source links

These links were collected with this event. Recorded source dates may reflect when a link was found. Article publication dates are shown only when available from the source. Open the originals for their full context.

  1. Novartis's Latest Trial Setback Sinks Stock ↗morningstar.com · Recorded source date: Sep 8, 2026, 8:48 AM UTC
  2. Novartis twin drug setbacks pile pressure on pipeline and CEO ↗finance.yahoo.com · Recorded source date: Sep 8, 2026, 11:47 AM UTC

AI-assisted, source-based analysis. Methodology · Report a correction

Connected by topic or specific details. Dates below are publication dates; the articles may describe separate events.

EARLIER READING

Novartis shares fall after pelacarsen trial failure

Novartis shares fell 1.9% after failure of the pelacarsen trial erased CHF4.9 billion in market value. The setback affects development of the company's cardiovascular treatment candidate.

Related details in the reporting

MORE RECENT READING

Amgen shares fall after trial failure clouds cholesterol-drug prospects

Amgen shares fell 10% after a Novartis trial failure raised concerns about the cholesterol-drug class; Novartis shares reportedly fell 14%. The development affected major pharmaceutical companies and investor expectations.

Related details in the reporting

More in Markets & economy → · Browse the event archive →